pharmacologic approaches to glycemic treatment for type 1 and type 2 diabetes involve addressing therapeutic inertia by empowering patients, optimizing care, and leveraging tools and technology. clinicians should schedule diabetes-only visits, set shared goals, and integrate screening for social and emotional barriers. they should prescribe thoughtfully, refer to diabetes self-management education and support (dsmes), and ensure patients know they are supported. to optimize care, clinicians should conduct practice-based screening for therapeutic inertia, create personalized care plans, and use a team-based approach to improve engagement. a1c and glucose data should drive rapid-cycle treatment intensification, and follow-up should be stratified based on these data. tools and technology can enhance communication and decision-making, including using a diabetes treatment algorithm and patient registry. for type 2 diabetes, injectable therapy may be appropriate in certain cases, particularly in patients with heart failure, chronic kidney disease, or established cardiovascular disease. the use of glucose-lowering medications should consider social determinants of health and individual risk factors. clinicians should also ensure patients on insulin therapy have education and supplies for proper administration, glucose monitoring, and hypoglycemia prevention. timely follow-up visits are essential to avoid therapeutic inertia and adjust care plans as needed.pharmacologic approaches to glycemic treatment for type 1 and type 2 diabetes involve addressing therapeutic inertia by empowering patients, optimizing care, and leveraging tools and technology. clinicians should schedule diabetes-only visits, set shared goals, and integrate screening for social and emotional barriers. they should prescribe thoughtfully, refer to diabetes self-management education and support (dsmes), and ensure patients know they are supported. to optimize care, clinicians should conduct practice-based screening for therapeutic inertia, create personalized care plans, and use a team-based approach to improve engagement. a1c and glucose data should drive rapid-cycle treatment intensification, and follow-up should be stratified based on these data. tools and technology can enhance communication and decision-making, including using a diabetes treatment algorithm and patient registry. for type 2 diabetes, injectable therapy may be appropriate in certain cases, particularly in patients with heart failure, chronic kidney disease, or established cardiovascular disease. the use of glucose-lowering medications should consider social determinants of health and individual risk factors. clinicians should also ensure patients on insulin therapy have education and supplies for proper administration, glucose monitoring, and hypoglycemia prevention. timely follow-up visits are essential to avoid therapeutic inertia and adjust care plans as needed.